Media headlines about AnaptysBio (NASDAQ:ANAB) have been trending somewhat positive on Friday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AnaptysBio earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.3070344207008 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
AnaptysBio (ANAB) traded down 0.13% during trading on Friday, reaching $67.72. The company’s stock had a trading volume of 8,695 shares. The company’s market cap is $1.38 billion. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00. The stock has a 50-day moving average price of $44.91 and a 200 day moving average price of $30.01.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. On average, analysts expect that AnaptysBio will post ($1.99) EPS for the current year.
Several analysts recently weighed in on ANAB shares. JMP Securities raised their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. Robert W. Baird started coverage on AnaptysBio in a research report on Monday, July 10th. They issued an “outperform” rating and a $36.00 target price for the company. Credit Suisse Group increased their target price on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Finally, Wedbush reiterated an “outperform” rating and issued a $75.00 target price (up from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $71.71.
ILLEGAL ACTIVITY NOTICE: “AnaptysBio (ANAB) Given Coverage Optimism Rating of 0.14” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/27/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-anaptysbio-anab-share-price.html.
In other news, major shareholder Holdings A/S Novo sold 70,706 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the transaction, the insider now directly owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 1,096,900 shares of company stock worth $23,321,392.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.